Web 2.0 for Pharma Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Web 2.0 for Pharma Innovation
Internal and external Web-based communities are changing how pharma companies can innovate.


Pharmaceutical Technology
Volume 35, Issue 9, pp. 14


Patricia Van Arnum
Innovation. Any company looks to new products and services to drive value and competitive advantage. Our emphasis in innovation typically focuses on what is made new or improved, but not on how we innovate. In facing shortfalls in achieving innovation, one may ask: "Was the problem the idea or the process used to generate the idea?" The short answer: it is both.

The practical ways to improve innovation in sourcing/procurement was discussed at a recent educational program of the Drug, Chemical, and Associated Technologies Association. Pharmaceutical companies, their suppliers, and other experts shared ways on how to cultivate and systemize innovation for generating actionable ideas for new or improved processes, products, or services, a particularly challenging task in sourcing/ procurement, where cost reduction is a primary and restrictive emphasis.

An interesting thread in this dialogue was the growing use among pharma companies of "innovation communities." These communities consist of employees in multiple functional areas, suppliers, customers, and other stakeholders that use Web-based platforms as a means to share ideas, information, and lessons learned. The premise is simple but important: engage people, internally and externally, in a structured, but accessible way to cultivate innovation.

A model for open innovation is Procter & Gamble's (P&G) "Connect + Develop" platform. According to P&G, more than 50% of its product initiatives involve collaboration from outside innovators. For pharma companies rethinking their innovation strategy, consider inside–outside innovation enabled by Web 2.0.

For additional insight, see "Strategies for Innovation in Pharmaceutical Sourcing and Procurement," at http://PharmTech.com/strategiesinnovation and "Innovation in Sourcing" at http://PharmTech.com/strategiesinnovation.

Patricia Van Arnum is a senior editor of Pharmaceutical Technology.

Read Patricia's blogs at http://blog.PharmTech.com/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here